# An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis

> **NCT02033317** · PHASE2 · TERMINATED · sponsor: **Relypsa, Inc.** · enrollment: 6 (actual)

## Conditions studied

- Hyperkalemia

## Interventions

- **DRUG:** patiromer

## Key facts

- **NCT ID:** NCT02033317
- **Lead sponsor:** Relypsa, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-08
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Study terminated due to slow enrollment
- **Last updated:** 2021-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02033317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02033317, "An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02033317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*